Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Pinus palustris* pollen extract is a biologic allergen extract derived from the pollen of the longleaf pine tree (*Pinus palustris*). It is primarily utilized in clinical settings for the diagnosis and treatment of IgE-mediated hypersensitivity reactions specifically triggered by longleaf pine pollen. As a diagnostic tool, the extract is used in percutaneous (skin prick) or intradermal testing to identify sensitization in patients with allergic rhinitis or asthma. As a therapeutic agent, it is employed in allergen-specific immunotherapy (ASIT), also known as desensitization. The mechanism involves the administration of gradually increasing doses of the allergen to modulate the patient's immune response, typically shifting the cytokine profile from a Th2-dominated allergic response to a Th1/Treg-mediated regulatory response, thereby inducing long-term immunological tolerance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pinus palustris pollen extract.